作者
Marco Hartmann-Rüppel

Dr. Marco Hartmann-Rüppel, Dipl.-Volkswirt

合伙人

Read More
Stephan Manuel Nagel

Stephan Manuel Nagel, LL.M. (EUI)

合伙人

Read More
作者
Marco Hartmann-Rüppel

Dr. Marco Hartmann-Rüppel, Dipl.-Volkswirt

合伙人

Read More
Stephan Manuel Nagel

Stephan Manuel Nagel, LL.M. (EUI)

合伙人

Read More

2020年4月14日

Temporary Framework adopted by the European Commission allows for specific cooperations among companies especially for critical hospital medicines

To avoid shortages in the supply of key medicines, the European Commission on 8th April 2020 announced a temporary relaxation of the relevant European competition rules and now allows for limited business cooperation between pharmaceutical companies to meet demand. The Temporary Framework for the assessment of antitrust issues relating business cooperations is intended in particular to ensure the supply of hospitals with medicines for coronavirus patients.

In this context, the Commission will also issue so called “comfort letters” concerning a specific cooperation project aimed at avoiding situations of shortages of critical hospital medicines. The Temporary Framework explains when and how firms can obtain guidance or written comfort in accordance with competition rules.

The Temporary Framework provides that manufacturers may coordinate more closely than normally permitted under European antitrust rules. This may apply to production, warehousing and possibly coordination of distribution, so that not all companies concentrate on one or a few medicines while other medicines are not produced in sufficient quantities.

The Communication on the Temporary Framework sets out the main criteria that the Commission will use when considering these possible cooperation projects. In particular, the Commission will not take action if the cooperation project is

  • objectively necessary to actually increase output in the most efficient way to address or avoid a shortage of supply of essential products or services, such as those that are used to treat COVID-19 patients;
  • temporary in nature (i.e. to be applied only as long there is a risk of shortage or in any event during the COVID-19 outbreak); and
  • not exceeding what is strictly necessary to achieve the objective of addressing or avoiding the shortage of supply.

The Commission’s press release of April 8th 2020 is available here.

Should you have any questions in this regard or require assistance with related or general antitrust law issues, please do not hesitate to contact us.

 

We have compiled on our website comprehensive information and recommendations for action in response to the legal implications arising from the coronavirus pandemic: Coronavirus - legal issues

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

The German Federal Supreme Court says Facebook must stop data collection and thus overturns the Higher Regional Court of Düsseldorf

2020年6月25日

作者

点击此处了解更多
商业和消费者合同

Things manufacturers need to consider when starting direct online sales

2020年4月23日

作者

点击此处了解更多
竞争、欧盟与贸易事务

Manufacturers and distributors of medical products increasingly in the focus of the competition authorities

2020年3月24日

作者 Dr. Marco Hartmann-Rüppel, Dipl.-Volkswirt 以及 Stephan Manuel Nagel, LL.M. (EUI)

点击此处了解更多